Molecular Basis for the Adjuvant Potential of Nigella sativa–Derived Bioactive Constituents in Overcoming Resistance to Cancer Therapy

Nasywa Zahirah Yustin; Ghani Phalosa; Feby Anastasya Sirait

doi:10.69693/ijim.v4i3.2068

Authors

Nasywa Zahirah Yustin The Republic of Indonesia Defense University
Ghani Phalosa The Republic of Indonesia Defense University
Feby Anastasya Sirait The Republic of Indonesia Defense University

DOI:

https://doi.org/10.69693/ijim.v4i3.2068

Keywords:

Nigella sativa, Thymoquinone, Cancer therapy resistance, Adjuvant therapy, Chemosensitization

Abstract

Resistance to cancer therapy remains a major cause of treatment failure, tumor recurrence, and disease progression because malignant cells can adapt through interconnected mechanisms involving prosurvival signaling, apoptosis suppression, drug efflux, epithelial–mesenchymal plasticity, cancer stemness, and the tumor microenvironment. This narrative review evaluates the molecular basis and adjuvant potential of Nigella sativa–derived bioactive constituents in overcoming resistance to conventional cancer therapies. Relevant literature was identified from Scopus, PubMed, Web of Science, ScienceDirect, and Google Scholar, with emphasis on resistance-related mechanisms, treatment sensitization, and combination-therapy studies. Among the identified constituents, thymoquinone has the strongest preclinical evidence. It modulates PI3K/Akt/mTOR, JAK/STAT, NF-κB, and Wnt/β-catenin signaling; enhances mitochondrial apoptosis; regulates ABC drug transporters; and influences autophagy, epithelial–mesenchymal transition, and cancer stem-cell properties. Thymoquinone has also enhanced the effects of chemotherapy, radiotherapy, and selected targeted agents in several experimental models, although treatment responses vary according to cancer type, dose, formulation, therapeutic combination, and microenvironmental conditions. Evidence for α-hederin, thymohydroquinone, dithymoquinone, thymol, and carvacrol remains comparatively limited, particularly in validated models of established treatment resistance. Clinical translation is further constrained by poor thymoquinone solubility and bioavailability, chemical instability, phytochemical variability, limited pharmacokinetic data, and insufficient evaluation of long-term safety and drug interactions. Overall, N. sativa-derived constituents, particularly thymoquinone, represent promising multi-target adjuvant candidates rather than alternatives to established cancer treatments. Future research should prioritize chemically standardized preparations, resistant cancer models, quantitative combination analyses, clinically relevant dosing, and well-designed pharmacokinetic, toxicological, and early-phase clinical studies.

Downloads

Download data is not yet available.

References

Abbas, M., Gururani, M. A., Ali, A., Bajwa, S., Hassan, R., Batool, S. W., Imam, M., & Wei, D. (2024). Antimicrobial properties and therapeutic potential of bioactive compounds in Nigella sativa: A review. Molecules, 29(20), Article 4914. https://doi.org/10.3390/molecules29204914

Abdel-Razek, A. G., Hassanein, M. M. M., Moawad, S., Farouk, A., Badr, A. N., Shehata, M. G., Siger, A., Grygier, A., & Rudzińska, M. (2024). Assessment of the quality, bioactive compounds, and antimicrobial activity of Egyptian, Ethiopian, and Syrian black cumin oils. Molecules, 29(21), 4985. https://doi.org/10.3390/molecules29214985

Al Bitar, S., Ballout, F., Monzer, A., Kanso, M., Saheb, N., Mukherji, D., Faraj, W., Tawil, A., Doughan, S., Hussein, M., Abou-Kheir, W., & Gali-Muhtasib, H. (2022). Thymoquinone radiosensitizes human colorectal cancer cells in 2D and 3D culture models. Cancers, 14(6), 1363. https://doi.org/10.3390/cancers14061363

Al-Damook, N., Sakkal, M., Khair, M., Mousa, W. K., Khoder, G., & Ghemrawi, R. (2025). Targeting cancer through thymoquinone: From molecular mechanisms to clinical prospects. International Journal of Molecular Sciences, 26(22), Article 11029. https://doi.org/10.3390/ijms262211029

Alsanosi, S., Sheikh, R. A., Sonbul, S., Altayb, H. N., Batubara, A. S., Hosawi, S., Al-Sakkaf, K., Abdullah, O., Omran, Z., & Alhosin, M. (2022). The potential role of Nigella sativa seed oil as epigenetic therapy of cancer. Molecules, 27(9), Article 2779. https://doi.org/10.3390/molecules27092779

American Association of Physicists in Medicine. (2021). Journal of applied clinical medical physics reference details. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm4.33

Ansary, J., Giampieri, F., Forbes-Hernandez, T. Y., Regolo, L., Quinzi, D., Gracia Villar, S., Garcia Villena, E., Tutusaus Pifarre, K., Alvarez-Suarez, J. M., Battino, M., & Cianciosi, D. (2021). Nutritional value and preventive role of Nigella sativa L. and its main component thymoquinone in cancer: An evidenced-based review of preclinical and clinical studies. Molecules, 26(8), Article 2108. https://doi.org/10.3390/molecules26082108

Arif, R., Bukhari, S. A., Mustafa, G., Ahmed, S., & Albeshr, M. F. (2024). Network pharmacology and experimental validation to explore the potential mechanism of Nigella sativa for the treatment of breast cancer. Pharmaceuticals, 17(5), Article 617. https://doi.org/10.3390/ph17050617

Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Chacon Castro, M. d. C., Deese, A. R., & Zhang, L. (2022). Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers, 14(19), Article 4562. https://doi.org/10.3390/cancers14194562

Bou Antoun, N., & Chioni, A.-M. (2023). Dysregulated signalling pathways driving anticancer drug resistance. International Journal of Molecular Sciences, 24(15), Article 12222. https://doi.org/10.3390/ijms241512222

Chen, Z., Xu, H., & Lin, Q. (2025). Targeting signaling pathways to overcome multidrug resistance in human cancers. MedComm, 5(2), Article e70295. https://doi.org/10.1002/mco2.70295

Chung, K. X., Wei, P. L. Y., & Akowuah, G. A. (2023). Different extraction methods for thymoquinone from Nigella sativa L. seeds and antioxidant activity. Indian Journal of Natural Products and Resources, 14(1), 75–80. https://doi.org/10.56042/ijnpr.v14i1.1134

Deng, X., Yang, Z., Chan, K. W., Ismail, N., & Abu Bakar, M. Z. (2024). 5-Fluorouracil in combination with calcium carbonate nanoparticles loaded with antioxidant thymoquinone against colon cancer: Synergistically therapeutic potential and underlying molecular mechanism. Antioxidants, 13(9), Article 1030. https://doi.org/10.3390/antiox13091030

Dong, J., Yuan, L., Hu, C., Cheng, X., & Qin, J.-J. (2023). Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review. Pharmacology & Therapeutics, 249, Article 108488. https://doi.org/10.1016/j.pharmthera.2023.108488

Fatfat, Z., Fatfat, M., & Gali-Muhtasib, H. (2021). Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells. World Journal of Clinical Oncology, 12(7), 522–543. https://doi.org/10.5306/wjco.v12.i7.522

Gueffai, A., Gonzalez-Serrano, D. J., Christodoulou, M. C., Orellana-Palacios, J. C., Lopez S. Ortega, M., Ouldmoumna, A., Kiari, F. Z., Ioannou, G. D., Kapnissi-Christodoulou, C. P., Moreno, A., & Hadidi, M. (2022). Phenolics from defatted black cumin seeds (Nigella sativa L.): Ultrasound-assisted extraction optimization, comparison, and antioxidant activity. Biomolecules, 12(9), Article 1311. https://doi.org/10.3390/biom12091311

Guler, E. M., Bozali, K., Huseyinbas, O., Celikten, M., & Kocyigit, A. (2025). Combination of 5-fluorouracil and thymoquinone for enhanced cytotoxicity, genotoxicity and apoptosis in colorectal cancer: In vitro and in vivo studies. Journal of Biochemical and Molecular Toxicology, 39(5), Article e70276. https://doi.org/10.1002/jbt.70276

Haiaty, S., Rashidi, M.-R., Akbarzadeh, M., Bazmani, A., Mostafazadeh, M., Nikanfar, S., Zibaei, Z., Rahbarghazi, R., & Nouri, M. (2021). Thymoquinone inhibited vasculogenic capacity and promoted mesenchymal–epithelial transition of human breast cancer stem cells. BMC Complementary Medicine and Therapies, 21, Article 83. https://doi.org/10.1186/s12906-021-03254-x

Kaushik, N., & Barmanray, A. (2025). Optimisation of ultrasound-assisted extraction conditions using response surface methodology and identification of thymoquinone from black cumin (Nigella sativa L.) seed extract. Food Technology and Biotechnology, 63(2), 262–273. https://doi.org/10.17113/ftb.63.02.25.8560

Khaikin, E., Chrubasik-Hausmann, S., Kaya, S., & Zimmermann, B. F. (2022). Screening of thymoquinone content in commercial Nigella sativa products to identify a promising and safe study medication. Nutrients, 14(17), 3501. https://doi.org/10.3390/nu14173501

Lei, Z.-N., Tian, Q., Teng, Q.-X., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z.-S. (2023). Understanding and targeting resistance mechanisms in cancer. MedComm, 4(3), Article e265. https://doi.org/10.1002/mco2.265

Majdalawieh, A. F., Al-Samaraie, S., & Terro, T. M. (2024). Molecular mechanisms and signaling pathways underlying the therapeutic potential of thymoquinone against colorectal cancer. Molecules, 29(24), Article 5907. https://doi.org/10.3390/molecules29245907

Moulana, M. S., Haiaty, S., Bazmani, A., Shabkhizan, R., Moslehian, M. S., Sadeghsoltani, F., Mostafazadeh, M., Asadi, M. R., Talebi, M., Jafari, Z., Morovati, M. R., Farzaei, M. H., & Rahbarghazi, R. (2024). Tumoricidal properties of thymoquinone on human colorectal adenocarcinoma cells via the modulation of autophagy. BMC Complementary Medicine and Therapies, 24, Article 132. https://doi.org/10.1186/s12906-024-04432-1

Neunert, G., Kamińska, W., & Nowak-Karnowska, J. (2025). Evaluating the thymoquinone content and antioxidant properties of black cumin (Nigella sativa L.) seed oil during storage at different thermal treatments. Applied Sciences, 15(1), Article 377. https://doi.org/10.3390/app15010377

Pal, R. R., Rajpal, V., Singh, P., & Saraf, S. A. (2021). Recent findings on thymoquinone and its applications as a nanocarrier for the treatment of cancer and rheumatoid arthritis. Pharmaceutics, 13(6), Article 775. https://doi.org/10.3390/pharmaceutics13060775

Pandey, R., Pandey, B., & Bhargava, A. (2025). An updated review on the phytochemistry and pharmacological activity of black cumin (Nigella sativa L.). Advanced Chinese Medicine, 2(1), 13–29. https://doi.org/10.1002/acm4.33

Safa, A. R. (2022). Drug and apoptosis resistance in cancer stem cells: A puzzle with many pieces. Cancer Drug Resistance, 5(4), 850–872. https://doi.org/10.20517/cdr.2022.20

Thabet, N. A., El-Khouly, D., Sayed-Ahmed, M. M., & Omran, M. M. (2021). Thymoquinone chemosensitizes human colorectal cancer cells to imatinib via uptake/efflux genes modulation. Clinical and Experimental Pharmacology and Physiology, 48(6), 911–920. https://doi.org/10.1111/1440-1681.13476

Vahitha, V., Lali, G., & AlSalhi, M. S. (2024). Unveiling the therapeutic potential of thymol from Nigella sativa L. seed: Selective anticancer action against human breast cancer cells (MCF-7) through down-regulation of Cyclin D1 and proliferative cell nuclear antigen (PCNA) expressions. Molecular Biology Reports, 51, Article 61.

Zafar, I., Safder, A., Afridi, H. I., Riaz, S., Ur-Rehman, R., Unar, A., Un Nisa, F., Gaafar, A.-R. Z., Bourhia, M., Wondmie, G. F., Sharma, R., & Kumar, D. (2023). In silico and in vitro study of bioactive compounds of Nigella sativa for targeting neuropilins in breast cancer. Frontiers in Chemistry, 11, Article 1273149. https://doi.org/10.3389/fchem.2023.1273149

Zhao, Z., Liu, L., Li, S., Hou, X., & Yang, J. (2023). Advances in research on the relationship between thymoquinone and pancreatic cancer. Frontiers in Oncology, 12, Article 1092020. https://doi.org/10.3389/fonc.2022.1092020

Zhou X, Wang F, Wu H, Chen X, Zhang Y, Lin J, Cai Y, Xiang J, He N, Hu Z, Jin X. Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells. Int J Biol Sci 2021; 17(13):3456-3475. doi:10.7150/ijbs.60401. https://www.ijbs.com/v17p3456.htm